Last reviewed · How we verify
Cholecystokinin
Cholecystokinin is a Small molecule drug developed by University Hospital, Gentofte, Copenhagen. It is currently in Phase 1 development for Pancreatic function test.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cholecystokinin |
|---|---|
| Sponsor | University Hospital, Gentofte, Copenhagen |
| Target | Cholecystokinin receptor type A, Gastrin/cholecystokinin type B receptor, Cholecystokinin receptor type A |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 1 |
Approved indications
- Pancreatic function test
Common side effects
Key clinical trials
- Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC (NA)
- POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS (NA)
- Proglumide and Chemotherapy for Metastatic Pancreatic Cancer (PHASE2)
- A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms (PHASE1)
- The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying (NA)
- Fatty Acids in Airway Smooth Muscle of Asthmatics (NA)
- Effect of Coffee Consumption on Appetite Traits in Overweight and Obesity (NA)
- Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cholecystokinin CI brief — competitive landscape report
- Cholecystokinin updates RSS · CI watch RSS
- University Hospital, Gentofte, Copenhagen portfolio CI
Frequently asked questions about Cholecystokinin
What is Cholecystokinin?
What is Cholecystokinin used for?
Who makes Cholecystokinin?
What development phase is Cholecystokinin in?
What does Cholecystokinin target?
Related
- Target: All drugs targeting Cholecystokinin receptor type A, Gastrin/cholecystokinin type B receptor, Cholecystokinin receptor type A
- Manufacturer: University Hospital, Gentofte, Copenhagen — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Pancreatic function test
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing